Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies.

Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. Over 2,500 hematologic oncology specialists participated in the Eleventh Annual Meeting of the Society (SOHO 2023). Click for more information and registration for On-Demand content.

  • 7,558 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of more than 6,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription (US members) to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News

Do High Molecular Risk Mutations Increase Leukemia Risk in Myelofibrosis

The multicenter trial studied genetic mutations across three cohorts.

Dr. Nowakowski Gives an Inside Look at the FDA ODAC 'Yes' Vote to Polivy

Grzegorz Nowakowski, MD, recounts his experience serving on the FDA ODAC while reviewing the POLARIX data.

TP-3654 Monotherapy Well-tolerated in Relapsed or Refractory Myelofibrosis

Led by Dr. Lindsay Rein, the goal of the phase I/II trial was to evaluate the safety and efficacy of TP-3654.

Cilta-cel Improved Outcomes in Pretreated Multiple Myeloma Compared with Standard Care

Cilta-cel improved survival outcomes compared with standard care in patients with lenalidomide-refractory multiple myeloma.

First Data on Nemtabrutinib in Relapsed or Refractory Hematologic Malignancies

Nemtabrutinib induced a response in 75% of patients with CLL, and investigators established a phase II dose of 65 mg daily.

Patients with CLL Lack Known Resistance Mechanisms After Disease Progression

Patients with CLL who progressed after ibrutinib and venetoclax did not show mutations linked with treatment resistance.

Molecular Perturbations in Bone Marrow Cells Could Promote MDS

The study evaluated mesenchymal cell molecular features and sought modifications that might affect MDS.

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top